Oncology Brothers: Practice-Changing Cancer Discussions

ASCO 2026 GI Highlights: EMERALD-3, FIGHT-302, CIRCULATE, MATTERHORN

RASolute 302 Pancreatic Cancer Study with Daraxonrasib at ASCO 2026 – Dr. Brian Wolpin

ASCO 2026 Head & Neck AND Sarcoma Highlights – Drs. Samantha Armstrong & Ari Rosenberg

Challenging Cases - Treatment of Common EGFR Mutations in Metastatic Non-Small Cell Lung Cancer

Lung Cancer ASCO 2026 Highlights: LIBRETTO-432, CROWN Update, CHRYSALIS-2, HARMONi-6

RASolute-302 with Daraxonrasib - Game Changer at ASCO 2026 in Pancreatic Cancer

ESMO Breast 2026 Highlights - VERITAC-2, PREcoopERA, PHERGain, SATEEN/BRE-354, TROPION-Breast02

Challenging Cases in Relapsed/Refractory Acute Myeloid Leukemia (AML): Dr. Joshua Zeidner

Challenging Cases in Chronic Myeloid Leukemia (CML): Drs. Fadi Haddad & Gaby Hobbs

Managing Toxicities of BRAF-MEK Inhibitors in Non-Small Cell Lung Cancer – Dr. Melissa Johnson

BRAF V600E mutated non-small cell lung cancer treatment requires navigating the choice between BRAF-MEK inhibitor combinations and chemoimmunotherapy. Dr. Melissa Johnson, a thoracic medical oncologist, highlights that while the Dabrafenib and Trametinib regimen is well-established, Encorafenib and Binimetinib is incre...

Treating BRAF V600E Mutated Non-Small Cell Lung Cancer (NSCLC) with Dr. Gregory Riely

Managing Toxicities of Bispecific Antibodies in Multiple Myeloma–Drs. Hamza Hashmi & Cesar Rodriguez

Managing Toxicities of EGFR Inhibitors in Lung Cancer – Drs. Azam Farooqui & Joshua Sabari

How to Treat Metastatic NSCLC with Targetable Mutations – Treatment Algorithm with Dr. Eric Singhi

Metastatic non-small cell lung cancer treatment in the frontline setting requires a precision medicine approach centered on comprehensive DNA and RNA NGS testing. For common EGFR mutations, combination therapies such as amivantamab-lazertinib or osimertinib-chemotherapy offer superior progression-free and overall survi...

How to Treat Metastatic NSCLC W/O Targeted Mutations – Treatment Algorithm with Dr. Christine Garcia

How to Treat Localized Non-Small Cell Lung cancer – Treatment Algorithm with Dr. Sanjay Popat

Early-stage non-small cell lung cancer treatment requires comprehensive staging and upfront next-generation sequencing to guide curative-intent strategies. For resectable disease, neoadjuvant chemoimmunotherapy, such as the nivolumab-based regimen in CheckMate 816, significantly improves overall survival, though the ne...

How to Treat Small Cell Lung Cancer (SCLC) – Treatment Algorithm with Dr. Jacob Sands

Small cell lung cancer treatment has evolved significantly, shifting toward immunotherapy and targeted maintenance strategies. In limited-stage disease, concurrent chemoradiation followed by two years of durvalumab is the new standard of care, yielding substantial improvements in overall survival. For extensive-stage d...

Managing Toxicities of Colorectal Cancer Drugs / Systemic Therapy – Dr. Rona Yaeger

BREAKWATER Study for BRAF V600E Mutated Colorectal Cancer – Encorafenib + Cetuximab + Chemotherapy

Metastatic BRAF V600E colorectal cancer requires immediate NGS testing to guide treatment, as molecular status dictates therapeutic strategy. The BREAKWATER study establishes a new standard of care by combining Encorafenib and Cetuximab with a chemotherapy backbone (FOLFOX or FOLFIRI), which doubles overall survival fr...

How to Treat Colorectal Cancer – Treatment Algorithm with Dr. Smitha Krishnamurthi